

# Claire Paquet

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3483988/publications.pdf>

Version: 2024-02-01

118  
papers

3,190  
citations

185998

28  
h-index

182168

51  
g-index

134  
all docs

134  
docs citations

134  
times ranked

3954  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of sleep duration in middle and old age with incidence of dementia. <i>Nature Communications</i> , 2021, 12, 2289.	5.8	254
2	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
3	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.4	179
4	Oxidative stress increases BACE1 protein levels through activation of the PKR-eIF2 $\gamma$ pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 885-896.	1.8	139
5	Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex. <i>Journal of Neurology</i> , 2022, 269, 44-46.	1.8	127
6	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 41.	3.0	121
7	Cerebrospinal fluid amyloid- $\beta$ 42/40 ratio in clinical setting of memory centers: a multicentric study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 30.	3.0	101
8	Seizures in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2016, 87, 912-919.	1.5	81
9	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.4	81
10	Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. <i>European Journal of Human Genetics</i> , 2016, 24, 710-716.	1.4	77
11	Increased levels of cerebrospinal fluid JNK3 associated with amyloid pathology: links to cognitive decline. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 151-161.	1.4	75
12	Neuroinflammation and A $\beta$ Accumulation Linked To Systemic Inflammation Are Decreased By Genetic PKR Down-Regulation. <i>Scientific Reports</i> , 2015, 5, 8489.	1.6	70
13	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. <i>Alzheimer's and Dementia</i> , 2013, 9, 406-413.	0.4	63
14	Nepriylisin, cardiovascular, and Alzheimer's diseases: the therapeutic split?. <i>European Heart Journal</i> , 2015, 36, 902-905.	1.0	61
15	Relevance of A $\beta$ 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 138.	1.7	59
16	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
17	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. <i>Journal of Neurology</i> , 2014, 261, 144-151.	1.8	56
18	Modulation of Tau Phosphorylation by the Kinase PKR: Implications in Alzheimer's Disease. <i>Brain Pathology</i> , 2011, 21, 189-200.	2.1	55

#	ARTICLE	IF	CITATIONS
19	Increased Cerebrospinal Fluid Levels of Double-Stranded RNA-Dependant Protein Kinase in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2012, 71, 829-835.	0.7	52
20	PKR involvement in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 83.	3.0	52
21	Impact of the 2008-2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 297-305.	1.2	51
22	Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease. <i>Neurology</i> , 2020, 95, e953-e961.	1.5	50
23	Cerebrospinal Fluid PKR Level Predicts Cognitive Decline in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e53587.	1.1	46
24	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 38.	3.0	44
25	The PKR Activator PACT Is Induced by A $\beta$ : Involvement in Alzheimer's Disease. <i>Brain Pathology</i> , 2012, 22, 219-229.	2.1	40
26	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289.	3.9	39
27	STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation. <i>Immunology Letters</i> , 2020, 228, 129-134.	1.1	38
28	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32.	4.5	38
29	PKR downregulation prevents neurodegeneration and A $\beta$ -amyloid production in a thiamine-deficient model. <i>Cell Death and Disease</i> , 2015, 6, e1594-e1594.	2.7	32
30	Effect of active A $\beta$ immunotherapy on neurons in human Alzheimer's disease. <i>Journal of Pathology</i> , 2015, 235, 721-730.	2.1	31
31	Neuronal Phosphorylated RNA-Dependent Protein Kinase in Creutzfeldt-Jakob Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 190-198.	0.9	29
32	Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. <i>HIV Medicine</i> , 2013, 14, 311-315.	1.0	29
33	Cognitive decline and brainstem hypometabolism in long COVID: A case series. <i>Brain and Behavior</i> , 2022, 12, e32513.	1.0	29
34	Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1459-1471.	1.2	28
35	PKR knockout in the 5xFAD model of Alzheimer's disease reveals beneficial effects on spatial memory and brain lesions. <i>Aging Cell</i> , 2019, 18, e12887.	3.0	28
36	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.4	26

#	ARTICLE	IF	CITATIONS
37	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. <i>Neuroscience</i> , 2019, 420, 136-144.	1.1	25
38	Downregulated apoptosis and autophagy after anti- $\text{A}\beta$ immunotherapy in Alzheimer's disease. <i>Brain Pathology</i> , 2018, 28, 603-610.	2.1	24
39	Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 857-861.	1.2	22
40	Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 905-913.	1.2	21
41	Could PKR inhibition modulate human neurodegeneration?. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1455-1457.	1.4	20
42	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 88.	3.0	20
43	N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. <i>Brain</i> , 2022, 145, 2834-2848.	3.7	20
44	Emotional memory enhancement in respect of positive visual stimuli in Alzheimer's disease emerges after rich and deep encoding. <i>Cortex</i> , 2015, 65, 89-101.	1.1	19
45	CSF level of $\text{A}\beta$ predicts mortality in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 29.	3.0	19
46	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 27.	3.0	18
47	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of $\text{A}\beta$ and tau. <i>PLoS ONE</i> , 2019, 14, e0217026.	1.1	18
48	Effect of amyloid $\text{A}\beta$ immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase-3 $\beta$ . <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 445-457.	1.8	17
49	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. <i>BMJ Open</i> , 2019, 9, e026380.	0.8	17
50	The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3136.	1.8	17
51	Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review. <i>Frontiers in Nutrition</i> , 2021, 8, 807970.	1.6	17
52	Hyperuricemia, Gout, and the Brain: an Update. <i>Current Rheumatology Reports</i> , 2021, 23, 82.	2.1	17
53	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663.	0.8	16
54	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12314.	1.2	15

#	ARTICLE	IF	CITATIONS
55	A cortical form of CADASIL with cerebral A $\beta$ <sup>2</sup> amyloidosis. <i>Acta Neuropathologica</i> , 2010, 120, 813-820.	3.9	14
56	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. <i>Neurobiology of Disease</i> , 2013, 54, 486-491.	2.1	14
57	Diagnosis associated with Tau higher than 1200â€”pg/mL: Insights from the clinical and laboratory practice. <i>Clinica Chimica Acta</i> , 2019, 495, 451-456.	0.5	13
58	Positive effects of lumbar puncture simulation training for medical students in clinical practice. <i>BMC Medical Education</i> , 2021, 21, 18.	1.0	13
59	Time Orientation and 10 Years Risk of Dementia in Elderly Adults: The Three-City Study. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1411-1418.	1.2	12
60	Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	12
61	The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. <i>Journal of Neurology</i> , 2014, 261, 1187-1195.	1.8	11
62	Dual Kinase Inhibition Affords Extended in Vitro Neuroprotection in Amyloid- $\beta$ Toxicity. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1659-1670.	1.2	11
63	Blood-Based Kinase Assessments in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 338.	1.7	11
64	Pro-Apoptotic Kinase Levels in Cerebrospinal Fluid as Potential Future Biomarkers in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 168.	1.1	10
65	Brimapitide Reduced Neuronal Stress Markers and Cognitive Deficits in 5XFAD Transgenic Mice. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 665-674.	1.2	10
66	Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, A $\beta$ <sup>242</sup> , and A $\beta$ <sup>240</sup> in Probable Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 791-802.	1.2	10
67	Increased Cerebrospinal Fluid Tau Levels in Logopenic Variant of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 611-616.	1.2	9
68	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 889-897.	1.2	9
69	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 903-911.	1.2	9
70	Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly. <i>Revue Neurologique</i> , 2020, 176, 677-683.	0.6	9
71	High-sensitivity quantification of acetylcholine and choline in human cerebrospinal fluid with a validated LC-MS/MS method. <i>Talanta</i> , 2021, 224, 121881.	2.9	9
72	New highly sensitive rodent and human tests for soluble amyloid precursor protein alpha quantification: preclinical and clinical applications in Alzheimer's disease. <i>BMC Neuroscience</i> , 2012, 13, 84.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?. Alzheimer's and Dementia, 2015, 11, 1125-1126.	0.4	8
74	Frontotemporal dementia is the leading cause of $\text{A}\beta^{42}/\text{A}\beta^{40}$ profiles defined with $\text{A}\beta^{42}/\text{A}\beta^{40} > 42/40$ ratio. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 161-169.	1.2	8
75	Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. Alcoholism: Clinical and Experimental Research, 2021, 45, 561-565.	1.4	8
76	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. Alzheimer's Research and Therapy, 2020, 12, 168.	3.0	7
77	Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review. Diagnostics, 2021, 11, 754.	1.3	7
78	Using virtual reality in lumbar puncture training improves students learning experience. BMC Medical Education, 2022, 22, 244.	1.0	7
79	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.4	7
80	Dose-dependent neuroprotective effect of the JNK inhibitor Brimapitide in 5xFAD transgenic mice. Brain Research, 2020, 1727, 146587.	1.1	6
81	Effect of anti-cancer drugs on microglia in patient-derived breast cancer xenografted mouse models. Neuropathology, 2017, 37, 91-93.	0.7	4
82	Bright light therapy improved sleep disturbances in a patient with dementia with Lewy bodies. Psychogeriatrics, 2020, 20, 124-125.	0.6	4
83	STAT3 inhibition reverses neuroinflammation and $\text{A}\beta$ metabolism induced by systemic inflammation. Alzheimer's and Dementia, 2020, 16, e041019.	0.4	4
84	Quantification of the trans-synaptic partners neurexin-neuroigin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. EBioMedicine, 2022, 75, 103793.	2.7	4
85	Brain Glucose Metabolism in Cerebral Amyloid Angiopathy. Stroke, 2021, 52, 1478-1482.	1.0	3
86	Determinants of Post-Operative Cognitive Decline in Elderly People. Journal of Prevention of Alzheimer's Disease, The, 2021, 8, 1-7.	1.5	3
87	Telemedicine in French Memory Clinics During the COVID-19 Pandemic. Journal of Alzheimer's Disease, 2022, 86, 525-530.	1.2	3
88	Biogenesis and regulation of microRNA: implication in Alzheimer's disease. Future Neurology, 2010, 5, 839-850.	0.9	2
89	O2501: CEREBROSPINAL FLUID SYNAPTIC VESICLE GLYCOPROTEIN 2A IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P545.	0.4	2
90	Association of Amyotrophic Lateral Sclerosis and Alzheimer's Disease: New Entity or Coincidence? A Case Series. Journal of Alzheimer's Disease, 2021, 84, 1439-1446.	1.2	2

#	ARTICLE	IF	CITATIONS
91	Could ryanodine receptor dysfunction be linked to PKR brain accumulations in Alzheimer's disease?. Medical Hypotheses, 2018, 113, 45.	0.8	1
92	Increased PKR level in human CADASIL brains. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 771-774.	1.4	1
93	The Diagnostic Value of a Short Memory Test: The TNI-93. Journal of Alzheimer's Disease, 2021, , 1-11.	1.2	1
94	Is there a link between headache and cognitive disorders? A systematic review. Revue Neurologique, 2022, 178, 285-290.	0.6	1
95	Biomarqueurs du liquide cÃ©rÃ©brospinal dans la maladie d'Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 307-320.	0.0	1
96	O3Ã©14Ã©06: DISSECTION OF SYNAPTIC PATHWAYS THROUGH THE ANALYSIS OF BIOMARKERS IN THE CSF: A COMBINING TOOL FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1061.	0.4	0
97	P1Ã©092: NEUROPROTECTIVE EFFECTS OF PKR KNOCKOUT IN 5XFAD ALZHEIMER MICE AND NEURONÃ©MICROGLIA COÃ©CULTURES. Alzheimer's and Dementia, 2018, 14, P306.	0.4	0
98	P3Ã©249: COMBINING MATHEMATICAL MODEL AND CATECHOLAMINE QUANTIFICATIONS TO SCREEN ALZHEIMER DISEASE FROM A SIMPLE BLOOD TEST. Alzheimer's and Dementia, 2018, 14, P1168.	0.4	0
99	P2Ã©277: CORTICAL SULCI WIDTH AND INCIDENT DEMENTIA IN OUTPATIENTS ATTENDING FRENCH MEMORY CLINICS: THE MEMENTO COHORT. Alzheimer's and Dementia, 2018, 14, P784.	0.4	0
100	CSF levels of the BACE1 substrate Neuregulin1 correlate with cognition and synaptic biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037097.	0.4	0
101	InÃ©vivo characterization of progressive amnesic syndrome due to suspected neurodegenerative nonÃ©Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039587.	0.4	0
102	Memory assessment in illiterate patients: The diagnostic value of the TNI 93. Alzheimer's and Dementia, 2020, 16, e042059.	0.4	0
103	Association of Alzheimer's disease and amyotrophic lateral sclerosis: A series of cases and review of the literature. Alzheimer's and Dementia, 2020, 16, e045814.	0.4	0
104	BloodÃ©based detection of earlyÃ©stage Alzheimer using multiomics and machine learning. Alzheimer's and Dementia, 2020, 16, e047334.	0.4	0
105	Cerebrospinal fluid neurogranin in Alzheimer's disease studies: are immunoassay results interchangeable?. Clinical Chemistry and Laboratory Medicine, 2021, 60, e13-e17.	1.4	0
106	Diagnostic prÃ©coce et biomarqueurs biologiques de la maladie d'Alzheimer. NPG Neurologie - Psychiatrie - Geriatrie, 2020, 20, 120S7-120S10.	0.1	0
107	Alcohol misuse can mimic frontotemporal degeneration in Alzheimer's disease patients. Revue Neurologique, 2021, , .	0.6	0
108	Biomarqueurs de la maladie d'Alzheimer: des avancÃ©es trÃ©s rapides. La Presse MÃ©dicale Formation, 2022, , .	0.1	0

#	ARTICLE	IF	CITATIONS
109	Telemedicine in French memory clinics during Covid-19 crisis. Alzheimer's and Dementia, 2021, 17, e052037.	0.4	0
110	Long-term cognitive and motor decline across the spectrum of Lewy body disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
111	Plasma p-tau231 in the Alzheimer's disease continuum: A multi-cohort evaluation of diagnostic performance, detection of A $\beta$ 2 pathology and preclinical application. Alzheimer's and Dementia, 2021, 17, .	0.4	0
112	Title is missing!. , 2020, 17, e1003289.		0
113	Title is missing!. , 2020, 17, e1003289.		0
114	Title is missing!. , 2020, 17, e1003289.		0
115	Title is missing!. , 2020, 17, e1003289.		0
116	Title is missing!. , 2020, 17, e1003289.		0
117	Title is missing!. , 2020, 17, e1003289.		0
118	Title is missing!. , 2020, 17, e1003289.		0